Outcome and prognosis of severe thrombotic microangiopathies treated by plasma exchange

Medical Science Monitor

Volumn 12, Issue 7, 2006, Pages

  Federici, Laure ^a   Klouche, Kada ^a   Amigues, Laurent ^a   Kanouni, Tarik ^a   Lopez Martinez, Ernesto ^a   Latry, Pascal ^a   Beraud, Jean Jacques ^a   Rossi, Jean François ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Hemolytic uremic syndrome; Intensive care unit; Plasma exchange therapy; Prognosis; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

ADULT; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLASGOW COMA SCALE; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MALE; MORTALITY; NEOPLASM; OUTCOME ASSESSMENT; PLASMAPHERESIS; PROGNOSIS; REVIEW; SURVIVAL RATE; THERAPY DELAY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PROGNOSIS; THROMBOSIS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 33745822724     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Terrell DR, Williams LA, Vesely SK et al: The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. J Thromb Haemost, 2005; 3: 1432-36
2. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry. A community perspective of patients with clinically diagnosed TTP-HUS: Semin Hematol, 2004; 41: 60-67
3. Moake JL: Thrombotic microangiopathies: N Engl J Med, 2002; 347: 589-600
4. Ruggenenti P, Remuzzi G: Pathophysiology and management of thrombotic microangiopathies. J Nephrol, 1998; 11: 300-10
5. Remuzzi G, Garella S: HUS and TTP: variable expression of a single entity. Kidney Int, 1987; 32: 292-308
6. Ruggenenti P, Noris M, Remuzzi G: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int, 2001; 60: 831-46
7. Furlan M, Lämmle MD: Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol, 2001; 14: 437-54
8. Mitra D, Jaffe EA, Weksler B et al: Thrombotic thrombocytopenic purpura and sporadic hemolytic uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood, 1997; 89: 1224-34
9. Rock GA, Shumak KH, Buskard NA et al: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apherisis Study Group. N Engl J Med, 1991; 325: 393-97
10. Dervenoulas J, Tsirigotis P, Bollas G et al: Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol, 2000; 79: 66-72
11. Gasparovic V, Radonic R, Mejic S et al: Possibilities and limits of treatment in patients with thrombotic thrombocytopenic purpura. Intensive Care Med, 2000; 26: 1690-93
12. Pene F, Vigneau C, Auburtin M et al: Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Med, 2005; 31: 71-78
13. Furlan M, Robles R, Lämmle B: Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood, 1996; 87: 4223-34
14. Tsai HM, Lia ECY: Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med, 1998; 339: 1585-94
15. Rose M, Eldor A: High incidence of relapses in thrombotic thrombocytopenic purpura: a clinical study of 38 patients. Am J Med, 1987; 83: 437-44
16. Janssens U, Graf C, Graf J et al: Evaluation of SOFA score: a single-center experience of a medical intensive care unit in 303 consecutive patients with predominantly cardiovascular disorders. Intensive Care Med, 2000; 26: 1037-45
17. Rock G, Porta C, Bobbio-Pallavicini E: Thrombotic thrombocytopenic purpura treatment in year 2000. Haematologica, 2000; 85: 410-19
18. Bell WR, Braine HG, Ness PM, Kickler TS: Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med, 1991; 325: 398-403
19. Henon P: Treatment of thrombotic thrombocytopenic purpura: results of a multicenter randomized study. Presse Med, 1991; 20: 1761-67
20. Thompson CE, Damon LE, Ries CA, Linker CA: Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood, 1992; 80: 1890-95
21. Bobbio-Pallavicini E, Gugliotta L, Centurioni R et al: Antiplatelets agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematol, 1997; 82: 429-35
22. Hollenbeck M, Kutkuhn B, Aul C et al: Haemolytic-ureamic syndrome and thrombotic-tnrombocytopenic purpura in adults: clinical findings and prognostic factors for death and end-stage renal disease. Nephrol Dial Transplant, 1998; 13: 76-81
23. Retornaz F, Durand JM, Poullin P et al: Idiopathic thrombotic thrombocytopenic purpura or Moschowitz syndrome: current physiopathologic and therapeutic perspectives. Rev Med Interne, 2000; 21: 777-84
24. Cohen JA, Brecher ME, Bandarenko N: Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apheresis, 1998; 13: 16-19
25. Hayward CP, Sutton DMC, Carter WH et al: Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med, 1994; 154: 982-87
26. Sarode R, Gottschall JL, Aster RH, McFarland JG: Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol, 1997; 54: 102-7
27. Pereira A, Mazzara R, Monteagudo J et al: Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol, 1995; 70: 319-23
28. Debourdeau P, Zammit C, Souleau B et al: Treatment of thrombotic microangiopathies. Ann Med Interne, 1999; 150: 374-87
29. Blot E, Decaudin D, Veyradier A et al: Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency. Throm Res, 2002; 106: 127-30
30. Studt JD, Kremer Hovinga JA, Alberio L et al: Von Willebrand factor-cleaving protease (ADAMTS 13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory. Swiss Med WKLY, 2003; 133: 325-32
31. Mori Y, Wada H, Gabazza EC et al: Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion, 2002; 42: 572-80
32. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE: Effect of plasma exchange on plasma ADAMTS 13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood, 2004; 103: 4043-49
33. George JN: How I treat patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome. Blood, 2000; 96: 1223-29
34. Rock G, Shumak KH, Sutton DM et al: Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apherisis Group. Br J Haematol, 1996; 94: 383-86
35. Rock G, Anderson D, Clark W et al: Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. British J Hematol, 2005; 129: 79-86